OZURDEX, initially approved by the U.S.

Food and Drug Administration (FDA) in 200

9 as the first drug therapy for the treatment of macular edema following retinal
vein occlusion (RVO), received FDA approval for the treatment of non-infectious
ocular inflammation, or uveitis, affecting the posterior segment of the eye in
2010.
OZURDEX is a biodegradable implant that delivers an extended release of the corti
costeroid dexamethasone via intravitreal injection with Allergans proprietary and
innovative NOVADURsolid polymer delivery system.
Approved Uses
OZURDEX (dexamethasone intravitreal implant) is a prescription medicine that is a
n implant injected into the eye (vitreous) and used:
To treat adults with swelling of the macula (macular edema) following branch ret
inal vein occlusion (BRVO) or central retinal vein occlusion (CRVO)
To treat adults with noninfectious inflammation of the uvea (uveitis) affecting
the back segment of the eye